Latest filings (excl ownership)
SC TO-C
Information about tender offer
6 May 24
SC TO-C
Information about tender offer
30 Apr 24
SC14D9C
Written communication relating to third party tender offer
30 Apr 24
SC14D9C
Written communication relating to third party tender offer
29 Apr 24
SC14D9C
Written communication relating to third party tender offer
29 Apr 24
8-K
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
29 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
PRER14A
Preliminary revised proxy
22 Apr 24
PRE 14A
Preliminary proxy
11 Apr 24
S-8
Registration of securities for employees
7 Feb 24
10-K
2023 FY
Annual report
7 Feb 24
8-K
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
6 Feb 24
8-K
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
8 Jan 24
UPLOAD
Letter from SEC
2 Jan 24
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
14 Dec 23
10-Q
2023 Q3
Quarterly report
30 Oct 23
8-K
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
30 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
9 Aug 23
8-K
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
S-3ASR
Automatic shelf registration
3 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
3 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
S-8
Registration of securities for employees
7 Feb 23
10-K
2022 FY
Annual report
7 Feb 23
8-K
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
7 Feb 23
8-K
Entry into a Material Definitive Agreement
20 Jan 23
424B5
Prospectus supplement for primary offering
20 Jan 23
8-K
Other Events
18 Jan 23
424B5
Prospectus supplement for primary offering
18 Jan 23
8-K
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
3 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
3 Nov 22
Latest ownership filings
4
Change in insider ownership
24 Apr 24
4
Matthew L Sherman
20 Feb 24
4
Thomas Patrick Kelly
20 Feb 24
4
Jama Pitman
20 Feb 24
4
Steven L. Hoerter
20 Feb 24
4
Dashyant Dhanak
20 Feb 24
4
Daniel C. Martin
20 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
4
Change in insider ownership
9 Feb 24
SC 13G/A
Brightstar Associates LLC
9 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
6 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Matthew L Sherman
18 Jan 24
4
Dennis Leo Walsh
18 Jan 24
4
Jama Pitman
18 Jan 24
4
Franklin Stuart Friedman
18 Jan 24
4
Thomas Patrick Kelly
18 Jan 24
4
Patricia L Allen
18 Jan 24
4
Daniel C. Martin
18 Jan 24
4
Ron Squarer
18 Jan 24
4
Steven L. Hoerter
14 Dec 23
4
Thomas Patrick Kelly
14 Dec 23
4
Jama Pitman
14 Dec 23
4
Daniel C. Martin
14 Dec 23
4
Matthew L Sherman
14 Dec 23
4
Daniel C. Martin
1 Dec 23
144
Notice of proposed sale of securities
30 Nov 23
4
Matthew L Sherman
31 Oct 23
4
Jama Pitman
31 Oct 23
4
Daniel C. Martin
31 Oct 23
4
Thomas Patrick Kelly
31 Oct 23
4
Steven L. Hoerter
31 Oct 23
4
Matthew L Sherman
4 Oct 23
4
Dashyant Dhanak
19 Sep 23
3
Dashyant Dhanak
5 Sep 23